x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Ace Therapeutics provides target-based antidiabetic drug discovery services. Leveraging our expertise and innovative technology platforms, we can effectively save time and cost in your antidiabetic drug development program. Our targets cover diabetes-related receptors, enzymes and transporters. We are committed to developing safer and more effective antidiabetic drugs for specific diabetes targets to meet your diverse drug development needs.
The study of diabetes-related targets provides the basis for the development of novel antidiabetic drugs. Traditionally, insulin and its receptors have been important diabetes therapeutic targets, providing a range of effective drugs for diabetes management. In recent years, novel diabetes targets have been identified, such as AMPK, FBPase, GLP-1, GK, GPR-119, GSK-3, PTP1B, SGLT2, among others. The discovery of these novel targets offers promising prospects for the development of antidiabetic drugs with higher selectivity and specificity.
Fig. 1 The molecular targets of the 99 antidiabetic agents in
clinical trials. (Dahlén, A. D.; et al.,2022)
Ace Therapeutics provides target-based drug development strategies to help clients discover novel antidiabetic drugs. Our target-based antidiabetic drug discovery services focus on exploring drug functions from molecular mechanism studies, providing new ideas and targets for new drug screening and development. Our extensive team of experts has in-depth knowledge of the mechanism of action of different diabetes targets and can develop antidiabetic drugs with higher safety, efficacy and specificity for specific targets.
Receptor-targeted antidiabetic drugs can effectively regulate processes such as glucose homeostasis as well as insulin secretion. These receptors typically include G protein-coupled receptor 119 (GPR119), thyroid hormone receptor (THR), glucocorticoid receptor, and others.
Our scientists understand the important role of these receptors and their downstream signaling networks in the physiology and pathology of diabetes. We can provide antidiabetic drug screening, optimization and preclinical assessment services for different receptor targets according to our clients' needs, with the aim of opening up new avenues for the development of innovative diabetes therapies.
Diabetes-related enzymes are involved in a number of key processes, including glucose and lipid metabolism, energy regulation and insulin signaling pathways. The development of enzyme inhibitors, antagonists and activators targeting these enzymes represents an exciting new avenue for diabetes management.
Ace Therapeutics provides comprehensive drug development services tailored to the target and drug development needs of our client’s interests. Whether it is enzyme target selection, target-based drug screening and optimization, or preclinical efficacy assessment, we can provide customized solutions to meet our client’s needs.
Potential diabetes-related transporter targets may include those involved in glucose regulation and those involved in energy regulation, among others.
Ace Therapeutics offers transporter-targeted antidiabetic drug screening and assessment services. Whether your drug candidate is a small molecule, biologic, or other therapeutic agent we provide the relevant research models and study conditions that suit your research requirements, budget, and timeline.
Ace Therapeutics provides target-based antidiabetic drug discovery services by combining our multidisciplinary knowledge and expertise in the field of diabetes and drug discovery. From target research to the identification of antidiabetic drug candidates, every step of the process is subject to rigorous experimental design and data analysis. This ensures that we can help you discover novel antidiabetic drugs that are highly effective and safe.Please contact us for further information and assistance.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
